Different Phenotypes at Onset in Neuromyelitis Optica Spectrum Disorder Patients with Aquaporin-4 Autoimmunity by Youming Long et al.
February 2017 | Volume 8 | Article 621
Original research
published: 28 February 2017
doi: 10.3389/fneur.2017.00062
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Fabienne Brilot, 
University of Sydney, Australia
Reviewed by: 
Scott S. Zamvil, 
University of California 
San Francisco, USA  
Samar S. Ayache, 
Paris Est University Creteil, France
*Correspondence:
Cong Gao 
smilegaocong@126.com
Specialty section: 
This article was submitted to Multiple 
Sclerosis and Neuroimmunology, 
a section of the journal 
Frontiers in Neurology
Received: 16 July 2016
Accepted: 13 February 2017
Published: 28 February 2017
Citation: 
Long Y, Liang J, Wu L, Lin S, Gao C, 
Chen X, Qiu W, Yang Y, Zheng X, 
Yang N, Gao M, Chen Y, Wang Z and 
Su Q (2017) Different Phenotypes at 
Onset in Neuromyelitis Optica 
Spectrum Disorder Patients with 
Aquaporin-4 Autoimmunity. 
Front. Neurol. 8:62. 
doi: 10.3389/fneur.2017.00062
Different Phenotypes at Onset in 
neuromyelitis Optica spectrum 
Disorder Patients with aquaporin-4 
autoimmunity
Youming Long1,2, Junyan Liang1,2, Linzhan Wu1,2, Shaopeng Lin3, Cong Gao1,2*,  
Xiaohui Chen3, Wei Qiu4, Yu Yang4, Xueping Zheng5, Ning Yang6, Min Gao7,  
Yaotang Chen1,2, Zhanhang Wang8 and Quanxi Su9
1 Department of Neurology, the Second Affiliated Hospital of GuangZhou Medical University, Guangzhou, Guangdong 
Province, China, 2 Institute of Neuroscience and The Second Affiliated Hospital of Guangzhou Medical University, Key 
Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, 
Collaborative Innovation Center for Neurogenetics and Channelopathies, Guangzhou, China, 3 Department of Emergency, 
The Second Affiliated Hospital of GuangZhou Medical University, Guangzhou, Guangdong Province, China, 4 Department of 
Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China, 5 Department of 
Neurology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China, 6 Department of Neurology, 
The Fifth Affiliated Hospital of GuangZhou Medical University, Guangzhou, Guangdong Province, China, 7 Department of 
Neurology, The Second Chinese Medicine Hospital of Guangdong Province, Guangzhou, Guangdong Province, China, 
8 Department of Neurology, Guangdong 999 Brain Hospital, Guangzhou, Guangdong Province, China, 9 Department of 
Neurology, Yunfu City People’s Hospital, Yunfu, Guangdong Province, China
Background: Although rare, brain abnormalities without optic neuritis (ON) or trans-
verse myelitis (TM) diagnosed with neuromyelitis optica spectrum disorder (NMOSD) 
have been reported in patients positive for the aquaporin-4 (AQP4) antibody.
Objective: To analyze demographic and clinical differences among NMOSD patients 
without ON or TM, those with either ON or TM, and patients with simultaneous ON and 
TM at disease onset.
Methods: In this retrospective study, patients who were positive for the AQP4 antibody, 
as detected using a cell-based assay, at the Second Affiliated Hospital of Guangzhou 
Medical University in China were recruited. Demographic and clinical data were obtained 
from each patient’s medical record.
results: A total of 292 patients were included in this study and were divided into four 
subgroups based on their initial manifestations: (i) NMOSD without ON or TM (NMOSD-
ON−TM−, n = 70); (ii) NMOSD with ON (NMOSD-ON+, n = 95); (iii) NMOSD with TM 
(NMOSD-TM+, n = 116); and (iv) simultaneous ON and TM [neuromyelitis optica (NMO), 
n =  11]. We found that age at onset was lower in the NMOSD-ON−TM− group than 
that in the other groups. The interval from the first episode to relapse was shorter in the 
NMOSD-ON−TM− group than that in NMOSD-TM+ group. Cerebral spinal fluid white cell 
counts and protein levels were significantly higher in the NMOSD-ON−TM− group than 
those in the other groups. Lower Expanded Disability Status Scale scores were observed 
in the NMOSD-ON−TM− group. Brain abnormalities, including in area postrema and 
hemisphere lesions, were more frequent in the NMOSD-ON−TM− group. Kaplan–Meier 
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inTrODUcTiOn
Neuromyelitis optica (NMO) is generally a severe, idiopathic, 
immune-mediated inflammatory, demyelinating, and necrotizing 
disease that mainly involves the optic nerve and spinal cord, but 
rarely the brain. The presence of aquaporin-4 (AQP4) antibody 
in NMO (1) facilitates its distinction from multiple sclerosis, and 
many studies have shown that AQP4 autoimmune lesions outside 
the optic nerve and spinal cord are common (2, 3).
Limited forms of NMO, optic neuritis (ON) or transverse 
myelitis (TM), positive for the anti-AQP4 antibody are diagnosed 
as NMO spectrum disorder (NMOSD) (4, 5). Furthermore, 
increasing numbers of positive cases without optic nerve and 
spinal cord involvement have been reported, indicating that the 
requirement for the presence of either ON or TM may confound 
the definition of NMOSD (6). Previous reports have shown that 
many manifestations outside the optic nerve and spinal cord in 
patients with NMOSD occur frequently during the disease and 
may precede ON or TM by months or years (7–9). Thus, the 
international panel for NMO diagnosis has updated the defini-
tion of NMOSD to include the presence or absence of anti-AQP4 
antibody (2). A diagnosis of NMOSD with anti-AQP4 antibody 
requires several core clinical characteristics, including clinical 
syndromes or magnetic resonance imaging (MRI) findings 
related to optic nerve, spinal cord, area postrema, other brainstem 
locations, diencephalic, or cerebral presentations (2). Recently, 
some cases have been reported with abnormalities in skeletal 
muscle and retinal cells expressing AQP4, characterized by the 
presence of immune complex deposition and AQP4 loss (10, 11). 
Therefore, manifestations in patients positive for AQP4 antibody 
are heterogeneous.
Surprisingly, despite the interest in brain abnormalities of 
patients with NMO/NMOSD, patients displaying pure brain 
symptoms have been rarely reported (7, 9, 12). Here, we describe 
the initial and follow-up clinical manifestations of patients with 
NMOSD who initially presented with different phenotypes, 
especially those with pure brain symptoms.
PaTienTs anD MeThODs
Patients
This retrospective study was approved by the Ethics Committee of 
the Second Affiliated Hospital of Guangzhou Medical University, 
China. All patients provided informed consent in the present 
study. Data analysis was performed based on the Chinese laws 
for data protection.
Consecutive patients positive for AQP4 antibodies, as detected 
retrospectively using a cell-based assay at the Second Affiliated 
Hospital of Guangzhou Medical University, were recruited until 
August 2015. The following data were acquired from each patient’s 
medical record: age, sex, medication, number of demyelinating 
events, clinical characteristics, and cerebral spinal fluid (CSF) 
protein levels and white cell counts. The Expanded Disability 
Status Scale (EDSS) (13) was conducted in these patients during 
follow-up at their most recent interview. Relapse was defined as 
objective worsening of new neurological symptoms that lasted 
at least 24  h and was preceded by disease stability for at least 
1 month.
The patients were diagnosed as NMO/NMOSD based on the 
2006 NMO diagnostic criteria (14) and the recent international 
panel guidelines (2). Cases of longitudinally extensive transverse 
myelitis (LETM) and acute partial transverse myelitis (APTM) 
were confirmed using MRI (15, 16). Cases of ON were defined by 
acute or subacute, unilateral or bilateral vision loss.
The recruited patients were divided into the following four 
groups based on initial disease manifestation: (i) with ON 
(NMOSD-ON+); (ii) with TM (NMOSD-TM+); (iii) without ON 
and TM (NMOSD-ON−TM−); and (iv) with simultaneous ON 
and TM NMO.
aQP4 antibody Testing
All CSF and serum samples were stored at −80°C. AQP4 antibod-
ies were detected with a cell-based assay using a commercially 
available kit (Euroimmun, Luebeck, Germany) or by transfection 
of HEK293T cells with a construct containing human AQP4-M1 
and AQP4-M23 genes.
statistical analysis
All statistical analyses were conducted using Statistical Program 
for Social Sciences version 11.0 (SPSS, Chicago, IL, USA) 
software. The χ2-test was used for binary and categorical data. 
One-way ANOVA and Mann–Whitney U tests were used for 
continuous variables. A Kaplan–Meier analysis was performed 
to evaluate survival (time to relapse, conversion to NMO). The 
Kaplan–Meier analysis was compared between groups using log-
rank tests. Values of p less than 0.05 were considered significant.
analysis showed that patients in the NMOSD-ON−TM− group experienced earlier relapse 
than those in other groups. Conversion to NMO in the NMOSD-ON+ group was greater 
than that in the other groups. Only 14 patients (4.8%, 14/292) had pure brain abnormal-
ities, of which 12 had disease duration of several more years and 8 (57.1%) experienced 
relapses.
conclusion: NMOSD patients with different initial manifestations present with significant 
differences in clinical features during follow-up. Patients with long-term AQP4 autoimmu-
nity in the brain in the absence of ON or TM are not common.
Keywords: neuromyelitis optica, aquaporin-4, optic neuritis, myelitis, brain
TaBle 1 | Final diagnosis and distribution of patients in three subgroups.
groups N (%) of 
patients
age at 
onset 
(median)
Female/
male
no. (%) of 
immunosuppressive 
therapya
(NMOSD)-
ON−TM−
70 (100) 30 60/10 7 (10)
NMO* 38 (54.3) 30 35/3 3 (7.9)
RLETM 8 (11.4) 39 7/1 1 (12.5)
APTM 3 (4.3) 28 2/1 0
MON 3 (4.3) 30 3/0 0
RON 2 (2.9) 28.43 1/1 0
Othersb 16 (22.9) 26 12/4 3 (18.8%)
NMOSD-ON+ 95 (100) 37 83/12 22 (23.2%)
NMO* 78 (82.1) 38 69/9 20 (25.6%)
RON 12 (12.6) 37 9/3 2 (16.7%)
MON 5 (5.3) 25 5/0 0
NMOSD-TM+ 116 (100) 40 98/18 10 (8.6)
NMO* 51 (44.00) 42 44/7 5 (9.8)
RLETM 40 (34.5) 40 34/6 5 (12.5)
MLETM 22 (19.0) 43 17/5 0
APTM 3 (2.6) 36 3/0 0 (0)
NMO 11 (100) 49 11/0 2 (6.8)
NMOSD, neuromyelitis optica spectrum disorder; NMO, neuromyelitis optica; RLETM, 
recurrent longitudinal extensive transverse myelitis; MLETM, monophasic LETM; APTM, 
acute partial transverse myelitis; RON, recurrent optic neuritis; MON, monophasic ON.
aLong therapy with azathioprine, cyclophosphamide, methotrexate, and mycophenolate 
mofetil.
bPatients without optic neuritis (ON) and transverse myelitis (TM).
*Significantly different among the three groups (p < 0.0001).
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resUlTs
Patient Demographics
A total of 292 patients with positive AQP4 antibodies were 
included in this retrospective study. This cohort comprised 253 
females and 49 males (a female to male ratio of 6.49). Among 
these 292 participants, 178 (61%) were diagnosed with NMO 
and 114 (39%) with NMOSD based on their most recent follow-
up (2) (Table 1). Their mean age at onset was 38.1 ± 14.5 years 
(range, 4–79 years); 22 of the 292 patients (7.53%) were older than 
60 years at disease onset, and 10 (3.42%) were under 18 years old.
The initial symptoms of the four groups are shown in Figure 1. 
Group (i) comprised 95 patients (32.5%, 95/292) diagnosed 
with ON (NMOSD-ON+) at onset. The disease started with 
isolated left ON in 60/95 cases (63.2%), isolated right ON in 
19 (20%), and simultaneous bilateral ON in 16 (16.8%). Group 
(ii) consisted of 116 patients (39.7%, 116/292) diagnosed with 
TM (NMOSD-TM+) at onset. The disease started with LETM in 
113/116 cases (97.4%) and APTM in 3/116 (2.6%) cases. Cervical 
lesions were found in 46/116 (39.7%), thoracic lesions in 35/116 
(30.2%), and simultaneous cervical and thoracic lesions in 35/116 
(30.2%) patients. Group (iii) was composed of 70 patients (24%, 
70/292) without ON and TM (NMOSD-ON−TM−) at onset. 
The main brain symptoms observed included area postrema 
syndrome with hiccups or nausea and vomiting (44.2%, 31/70), 
acute brainstem syndrome (22.9%, 16/70), acute diencephalic 
clinical syndrome with NMOSD-typical diencephalic MRI lesions 
(17.1%, 12/70), and symptomatic cerebral syndrome (15.7%, 
11/70). At the most recent interview, 14 patients (4.8%, 14/292) 
had confirmed episodes involving brain abnormalities only, 
without ON or TM, of which the duration was >12 months for 
12 patients, 8 (57.1%) of whom experienced relapse. None of 
these patients were diagnosed as having NMO or NMOSD prior 
to the AQP4 antibody test. Two patients were from the same 
family, and their younger sister had been diagnosed with typical 
NMO with bilateral ON and LETM (Figure 2). Two patients had 
comorbidity of autoimmune nephritis. One case had comorbidity 
of anti-N-methyl-d-aspartate receptor encephalitis. Group 4 was 
composed of 11 patients (3.8%) diagnosed with simultaneous ON 
and TM (NMO) at onset.
comparison of nMOsD Phenotypes at 
Onset
The characteristics and phenotypes of the patients (n =  174) 
in the three NMOSD groups (NMOSD-ON+, NMOSD-TM+, 
and NMOSD-ON−TM−) who had complete MRI, CSF, demo-
graphic, and clinical data were compared. These three groups 
showed no significant differences in the sex ratio, disease dura-
tion, and number of relapsing cases (p >  0.05). However, the 
age at onset was lower in the NMOSD-ON−TM− group than 
that in the other two groups (p < 0.005). The interval from the 
first episode to relapse (relapse-free time) was shorter in the 
NMOSD-ON−TM− group than that in the NMOSD-TM+ group 
(p  =  0.027). In addition, a significant difference was found 
among these groups for the NMO conversion (p < 0.0001). The 
CSF white cell count and protein level were significantly higher 
in the NMOSD-ON−TM− group than those in the other two 
groups. The NMOSD-ON−TM− group had lower EDSS scores 
than the other two groups in the most recent follow-up. Brain 
MRI abnormalities in area postrema and hemisphere lesions 
were more frequent in the NMOSD-ON−TM− group (p < 0.005; 
Table 2), whereas brain MRI abnormalities were similar between 
the NMOSD-ON+ and NMOSD-TM+ groups. Pure cervical cord 
lesions were more frequent in the NMOSD-ON−TM− group 
(p < 0.01).
Follow-up and Kaplan–Meier analysis
Patients were included in this analysis if they had validated 
relapsing events that occurred from the time of the initial incident 
to the most recent interview and the duration of those symptoms 
was greater than 12 months. Thus, follow-up data were analyzed 
for 226 patients in the three NMOSD groups (NMOSD-ON+, 
NMOSD-TM+, and NMOSD-ON−TM−).
Among the 61 patients analyzed in the NMOSD-ON−TM− 
group, 60 (98.4%) experienced relapse, and 31 patients (50.8%) met 
the NMO diagnostic criteria during follow-up (12–268 months). 
Among the 80 patients analyzed in the NMOSD-TM+ group, 72 
patients (90%) experienced relapse, and 34 (42.5%) were diag-
nosed with NMO during follow-up (12–324  months). Among 
the 85 patients analyzed in the NMOSD-ON+ group, 80 patients 
(94.1%) experienced relapse, and 71 (83.5%) met the NMO diag-
nostic criteria during follow-up (12–346 months). The conversion 
to NMO in the NMOSD-ON+ group was greater than that in the 
other tow groups (p < 0.0001).
FigUre 2 | Three neuromyelitis optica/neuromyelitis optica spectrum 
disorder cases from the same family. (a) Case one is the oldest sister 
with autoimmune nephritis and the proband in this family. She experienced 
left limb weakness in 2004. A recent magnetic resonance imaging (MRI) scan 
showed a residual lesion in the posterior limb of internal capsule (arrow).  
(B) Case two is the second sister who experienced intractable hiccups and 
nausea and inappropriate antidiuretic hormone secretion in 2011. Her MRI 
showed a lesion in the dorsal medulla (arrow). (c,D) Case three, the third 
sister, had typical optic neuritis and transverse myelitis. Her MRI scan 
showed a lesion in the dorsal medulla and longitudinally extensive transverse 
myelitis (arrow).
FigUre 1 | Distribution of initial manifestations status in 292 patients. NMOSD, neuromyelitis optica spectrum disorder; ON, optic neuritis; TM, transverse 
myelitis; APTM, acute partial transverse myelitis; LETM, longitudinally extensive transverse myelitis; NMOSD-ON−TM−, patient initial manifestation without ON and 
TM; NMOSD-ON+, patient initial manifestation with ON; NMOSD-TM+, patient initial manifestation with TM; neuromyelitis optica (NMO), patient initial manifestation 
with simultaneous ON and TM.
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A Kaplan–Meier analysis revealed that compared with 
NMOSD-TM+ cases, NMOSD-ON−TM− patients experienced 
significantly earlier relapses after the first attack (p =  0.002). 
However, these two groups showed a similar relapse rate at 
late follow-up (>100  months) (Figure  3). Furthermore, com-
pared with NMOSD-ON+ cases, NMOSD-ON−TM− cases also 
experienced significantly earlier relapses (p =  0.023), although 
both of these groups had similar relapse rates at >50 months. The 
Kaplan–Meier analysis also revealed that the interval from first 
attack to NMO conversion differed among the groups (Figure 4). 
The median time of 120 months [95% confidence interval (CI): 
40.6–199.4  months] in NMOSD-TM+ cases was significantly 
longer than that of 49.0 months for the NMOSD-ON−TM− cases 
(95% CI: 26.8–71.2 months, p = 0.012) and 36.0 months for the 
NMOSD-ON+ cases (95% CI: 25.3–46.7 months, p < 0.0001).
DiscUssiOn
The present study found that initial manifestations without 
TM or ON were not uncommon in NMOSD patients. In all the 
patients examined, the onset of brain/brainstem lesions was more 
frequent than that previously shown in a large study (12). We 
observed that 19.5% (57/292) of patients had involvement in area 
postrema/brainstem, including displaying intractable hiccups 
and nausea (IHN) (10.6%, 31/29). Although increasing numbers 
of NMOSD patients with brain/brainstem-onset manifesta-
tions have been reported, such patients without ON and TM in 
NMOSD have been rarely reported in previously conducted large 
studies. For example, a relatively large study (12) reported 18% 
of patients positive for AQP4 antibodies without TM and ON 
presented with brain symptoms as their initial manifestation. In 
Japan, 28.6% (10/35) of cases showed IHN preceding ON and 
TM, and IHN was preceded by an episode of viral infection 
(17). Apiwattanakul et  al. reported that the initial presenting 
symptom of NMO was intractable vomiting in 12% of AQP4 
antibody-positive patients (8). In addition, hiccup and nausea 
often preceded neurological symptoms such as ON and TM, 
TaBle 2 | Demographic and paraclinical characteristics in three subgroups with valid data.
characteristics nMOsD-On−TM− nMOsD-TM+ nMOsD-On+ p1 p2 p3
(n = 53) (n = 57) (n = 64)
Age onset (years) 31.6 ± 17.8 41.6 ± 14.2 37.0 ± 14.2 <0.0001 0.012 NS
Age onset < 30 years, n (%) 31 (58.5) 10 (17.5) 18 (28.1) <0.0001 0.001 NS
Age onset >40 years, n (%) 16 (30.2) 30 (52.6) 25 (39.1) 0.017 NS NS
Age onset >50 years, n (%) 5 (9.4) 16 (28.1) 13 (20.3) 0.013 NS NS
Female/male 47/6 52/5 55/9 NS NS NS
Duration (months) 68.8 ± 58.8 76.6 ± 65.6 79.7 ± 68.4 NS NS NS
Relapsing cases, n (%) 48 (90.6) 48 (84.2) 62 (96.9) NS NS NS
Relapse-free time (months)a 4 (1–96) 14 (2–312) 8 (1–120) 0.027 NS NS
Neuromyelitis optica (NMO)-free time (months)b 24 (1–156) 24 (2–156) 16 (2–223) NS NS NS
Meeting 2006 NMO criteria, n (%) 31 (57.4%) 21 (36.8%) 58 (90.6) <0.0001 <0.0001 <0.0001
CSF protein (g/L) 0.44 ± 0.28 0.37 ± 0.20 0.27 ± 0.15 0.041 0.012 NS
CSF pleocytosis, n (%) 31 (58.5) 22 (38.6) 31 (48.4) NS NS NS
CSF cells (no./mm3) 8 (0–325) 5 (0–161) 5 (0–98) 0.005 0.050 NS
Median EDSS (range) 3 (1–10) 5 (1–10) 5 (1–10) 0.008 0.010 NS
EDSS ≤ 3, n (%) 27 (50.9%) 10 (17.5) 16 (25) <0.0001 <0.0001 <0.0001
EDSS ≥ 6, n (%) 10 (18.9%) 17 (29.8) 20 (31.3) NS NS NS
Death, n (%) 2 (3.8) 2 (3.5) 2 (3.1) NS NS NS
Brain NMO lesions in history
Area postrema lesions, n (%) 32 (60.4) 11 (19.3) 14 (21.9) <0.0001 <0.0001 NS
Brain stem lesions, n (%) 9 (17.0) 5 (8.8) 4 (6.3) NS NS NS
Diencephalic lesion, n (%) 25 (47.2) 3 (5.3) 9 (14.1) <0.0001 <0.0001 NS
Cerebral lesion, n (%) 15 (28.3) 2 (3.5) 4 (6.3) 0.001 0.001 NS
Spinal cord lesions in history 37 (69.8) 57 (100) 57 (89.1) <0.0001 0.009 0.010
LETM, n (%) 30/37 (81.1) 55/57 (96.5) 47/57 (82.5) 0.013 NS 0.015
Cervical lesions, n (%) 24/37 (64.9) 21/57 (36.8) 20/57 (35.1) 0.008 0.005 NS
Thoracic lesions, n (%) 6/37 (16.2) 16/57 (28.1) 25/57 (43.9) NS 0.005 NS
Cervical + thoracic lesions, n (%) 7/37 (18.9) 20/57 (35.1) 12/57 (21.1) NS NS NS
NMOSD, neuromyelitis optica spectrum disease; LETM, longitudinal extensive transverse myelitis; EDSS, Expanded Disability Status Scale; NMOSD-ON+, patient initial manifestation 
with ON; NMOSD-TM+, patient initial manifestation with TM; NMOSD-ON+TM+, patient initial manifestation with simultaneous optic neuritis (ON) and transverse myelitis (TM); CSF, 
cerebral spinal fluid; p1, comparison between NMOSD-ON−TM− and NMOSD-TM+ patients; p2, comparison between NMOSD-ON−TM− and NMOSD-ON+ patients; p3, comparison 
between NMOSD-ON+ and NMOSD-TM+ patients.
aDuration from the first attack to the first relapse.
bDuration from the first attack to diagnosis of NMO.
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and 14% (10/70) of newly identified AQP4-IgG-positive patients 
had nausea and vomiting as the initial presenting symptoms of 
NMOSD (18). Most brainstem attacks were first events and were 
regarded as monophasic brainstem symptoms until follow-up (19, 
20). However, a large study of 106 NMOSD patients seropositive 
for AQP4 antibodies reported that 4.7% (5/106) of patients had 
initial brain/brainstem manifestations without TM and ON (21). 
Another study from multiple centers showed only 2.3% (4/175) 
of NMOSD patients had brainstem-onset involvement (22). Our 
study found that 10.6% of patients had IHN, which is comparable 
to that found in a recent large study (8, 18). Therefore, IHN may 
have been underestimated in some previous studies because acute 
clinical events without TM or ON may have been overlooked, and 
some patients may have experienced lesion resolution. Although 
these patients had brain disease involvement before an ON or 
TM episode, most brain attacks were first events and almost all 
developed into NMO/NMOSD with ON and/or TM at follow-up 
(19, 20).
All groups in our cohort consisted of more females than males, 
consistent with observations in previous studies. Furthermore, 
the mean age at disease onset in patients presenting with ON was 
significantly lower than that in patients presenting with TM (9, 14, 
21, 22). In our study, patients with disease onset were >40 years of 
age; however, similar numbers presented with TM (52.6%) or ON 
(39.1%) (p > 0.005), indicating a predominance of disease onset 
in young patients without TM and ON. Their mean age at disease 
onset was similar to that reported in previous studies showing a 
younger mean age at disease onset in patients with only brain/
brainstem manifestations (9, 12). Thus, AQP4-mediated brain/
brainstem disease may occur in patients younger than those with 
ON and TM, supporting age-dependent anatomical susceptibility 
differences or differences in AQP4 antibody accessibility of the 
target organs (23). However, Afro-Caribbean patients (9) report-
edly have a younger age of disease onset, indicating ethnicity 
may be an important factor. Studies in China examining such 
differences would also be warranted.
The Kaplan–Meier analysis of our cohort demonstrated 
that >50% of patients experienced a relapse within 1.5 years of 
disease onset, and almost all experienced relapse within 10 years 
(Figure  3). Patients presenting with only brain/brainstem 
lesions had a shorter relapse-free time than those with ON or 
TM, a result similar to previous findings (22). There was a trend 
toward ON-onset patients relapsing sooner than TM-onset 
patients, which is in contrast to other studies in which AQP4 
antibody-positive patients with TM-onset had earlier relapse 
than ON-onset patients (21, 22). Patients without ON or TM at 
FigUre 3 | Kaplan–Meier analyses stratified by different groups: considering the end point is the first relapse. (a) Kaplan–Meier analysis revealed that 
patients in three groups would experience different relapsing time after the first attack (p = 0.001); (B,c) Kaplan–Meier analysis revealed that patients in MOSD-
ON−TM− group would experience earlier relapse after the first attack and was significantly different neuromyelitis optica spectrum disorder (NMOSD)-TM+ group and 
NMOSD-ON+ (p < 0.05); and (D) Kaplan–Meier analysis revealed no significant differences in time to the first relapse between NMOSD-ON+ and NMOSD-TM+ group 
(p = 0.186).
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onset had more lesions in areas without an intact blood–brain 
barrier, indicating that AQP4-mediated relapsing episodes may 
precede other neurological symptoms. However, it is unclear why 
lesions in these areas are less common than ON and spinal cord 
lesions (17).
We observed a different median time for NMO to develop in the 
three subgroups, as reported previously (21); however, the median 
time was relatively short in our cohort. Additionally, patients 
presenting with ON had a higher probability of developing NMO 
over time than those presenting with TM or brain/brainstem 
episodes. This may be because AQP4-mediated monophasic or 
relapsing ON is underrecognized, and prophylactic immunosup-
pressant therapy is not readily available (21). However, in our 
cohort, >60% of patients with TM did not develop NMO based 
on the 2006 diagnostic criteria (14), and even relapsing patients 
experienced a delay of >20 years. Therefore, our results support 
the ideas that AQP4-mediated disease is not synonymous with 
the classical description of NMO and that the first manifestations 
reflect different NMO phenotypes.
In our cohort, fewer patients presenting with brain disease 
progressed to NMO (31/61, 50.8%) compared with those in 
a study examining Korean patients (10/15, 66.7%) (12), which 
may be associated with the small sample size used in their study. 
Interestingly, some of our patients lacked typical ON and TM at 
onset attack, with an interval of years between onset attack and 
first episodes of ON or TM. However, AQP4 antibody-positive 
patients with manifestations suggesting long-term brain/brain-
stem involvement without ON and TM, especially those with 
a relapsing course, have been rarely reported (7, 9, 24–27). We 
found 12 patients (4.1%, 12/292) with episodes involving the 
brain without ON or TM over years, which is higher than the 2.4% 
(7/289) detected in Japan (9). In the present retrospective analysis, 
all patients with manifestations suggestive of brain involvement 
at onset were misdiagnosed with other diseases because of their 
atypical and complicated manifestations. Isolated lesions in the 
supratentorial region of the brain were rarely observed in the 
present study and have only been described in single case reports 
(7, 24–27). Atypical manifestations make diseases more difficult 
to diagnose, indicating AQP4 antibody-positive patients with 
long-term relapsing symptoms other than ON or TM may be 
easily misdiagnosed without the detection of AQP4 antibodies. 
Additionally, some patients with phenotypic presentations sug-
gestive of brain disease presented concomitantly with an immune 
disorder involving another organ; for example, two patients had 
immunological disorders of the kidney. Previously, recurrent 
hyperCKemia accompanying AQP4-IgG seropositivity reflected 
FigUre 4 | Kaplan–Meier analyses stratified by different groups: considering the conversion to neuromyelitis optica (nMO). (a) Kaplan–Meier analysis 
revealed that patients in three groups would experience different time of NMO conversion after the first attack (p < 0.0001); (B) Kaplan–Meier analysis revealed that 
patients in MOSD-ON−TM− group would experience earlier NMO event after the first attack and was significantly different neuromyelitis optica spectrum disorder 
(NMOSD)-TM+ group (p = 0.012); (c) Kaplan–Meier analysis revealed no significant differences in time to the NMO event between NMOSD-ON+ and MOSD-
ON−TM− group (p = 0.081); and (D) Kaplan–Meier analysis revealed patients in NMOSD-ON+ group would experienced earlier NMO event after the first attack and 
was significantly different NMOSD-TM+ group (p < 0.0001).
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pathogenic IgG targeting of skeletal muscle AQP4 (10). However, 
no typical AQP4 loss in kidney could be found with biopsy in 
our cases, although the AQP4 expression was relatively weaker 
than that in the control (not shown). Therefore, whether autoim-
mune AQP4 in the kidney is associated with NMOSD should be 
examined further, because AQP4-IgG seropositive cases do not 
meet the present definition of NMOSD, indicating that they may 
be autoimmune AQP4 channelopathies (3).
Mortality was significantly different in the three subgroups. 
First, the most recent median EDSS scores were lower in patients 
with brain/brainstem manifestations compared with those with 
ON or TM attacks at onset. Second, further analysis showed 
that compared with patients with ON, more patients with brain/
brainstem manifestations had EDSS scores <3.0, and there was a 
trend toward fewer brain/brainstem-onset patients having EDSS 
scores >6.0. The prognosis for ON-onset patients was worse, and 
this may be related to a high proportion of these patients with 
NMO development, resulting in visual and motor disabilities. 
Although a low proportion of TM-onset patients developed 
NMO, their older age and increased proportion with LETM 
may be important factors for mortality. Older-onset patients are 
reportedly more likely to present with LETM and have a high 
risk of developing motor disability (21). It was previously shown 
that brain lesions with AQP4 autoimmunity in patients with 
NMOSD are accompanied by discontinued vasogenic edema 
(14). Thus, brain/brainstem-onset patients with recurrent brain/
brainstem lesions may be predisposed to revisable edema without 
axonal injury resulting in slight persistent disability. Effective 
immunosuppressive treatment with good tolerance may prevent 
relapse or conversion to NMO. However, although some patients 
followed immunosuppressive regimes, >80% of these patients 
started treatment with only high-dose corticosteroids, tapering 
over several months to low-dosage steroids. The potential benefit 
of immunosuppressive therapy was not observed in the present 
cohort because of low use. In China, long-term immunosuppres-
sive treatment is limited by adverse effects, patient compliance, 
and poor doctor–patient relationships (28). We believe that using 
recommended first-line long-term immunosuppression would 
provide a better prognosis.
The present study had some limitations. First, there was a 
selection bias because of the retrospective nature of the study 
and because some patients had incomplete data. Furthermore, 
a recall bias might result from data collection acquired from 
a patient’s medical record or interview. Second, detection of 
AQP4 was retrospective; therefore, AQP4 status at the initial 
episode was unknown. Although prospective studies are 
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important, the current study is valid and will help clinicians 
treat different phenotypes of NMOSD. Third, our study focus is 
limited on the AQP4-positive NMOSD patients, which allows 
for a clear disease population, but leaves out AQP4-negative 
NMOSD. In particular in the latter disease group, would an 
analysis of the different phenotypes be of diagnostic importance 
and guidance for treatment decision. Given the recent insights 
into the role of antibodies against native conformational myelin 
oligodendrocyte glycoprotein (MOG) (29), embedding the 
data on NMOSD with mere brain involvement in this context 
would give a more comprehensive and up-to date picture of 
the patients with an “NMOSD phenotype” and brain involve-
ment. Therefore, detection of MOG antibody is necessary in 
our further study.
In summary, we observed significant differences in clinical fea-
tures during follow-up among NMOSD patients who presented 
with different initial manifestations. Patients who presented 
without ON and TM as their initial manifestations were younger 
at onset and had earlier relapses and more brain abnormalities but 
better prognosis than those who presented with ON and TM. The 
conversion to NMO in patients with TM at onset was lower than 
that in the other patient groups. Furthermore, the conversion to 
NMO was more frequent in patients with ON at onset than that 
in patients with brain/brainstem manifestations at onset. Patients 
with long-term AQP4 autoimmunity in the brain in the absence 
of ON or TM were not common.
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